Medications
Nivolumab in head and neck squamous cell carcinoma: Added benefit for specific patients
Nivolumab (trade name: Opdivo) has been approved since June 2017 for adults with squamous cell carcinoma of the head and neck. The drug is an option if platinum-based chemotherapy is not sufficiently effective against this ...
Sep 6, 2017
0
0